Amphastar Pharmaceuticals Inc vs Core Scientific Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Core Scientific Inc trades at $20.21 (market cap $6.25B). The key difference: Core Scientific Inc is far larger — about 7.2× Amphastar Pharmaceuticals Inc's market cap, and Core Scientific Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | CORZ | |
|---|---|---|
Market Cap | $863.95M | $6.25B |
Sector | Health | Technology |
52-Week High | $30.81 | $29.16 |
52-Week Low | $16.87 | $13.55 |
Enterprise Value | $1.26B | $8.78B |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Core Scientific (CORZ) trades at $21.01, down 0.19% on the day, with technical indicators showing a bearish trend despite neutral oscillators. The company reported Q2 2026 revenue growth but missed earnings expectations with a significant net loss of -$1.4 billion for 2026. Recent news highlights a major partnership with AMD for AI infrastructure development, potentially driving future revenue growth through colocation services.
While analyst consensus remains strongly bullish with an 86% buy rating and $35.88 price target, fundamental risks include persistent negative profit margins and substantial cash burn. The AMD partnership offers significant upside potential, but investors must weigh execution risks against the company's current unprofitability and competitive pressures in the data center market.
Trailing returns across standard periods
Latest headlines on both assets
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →